|
Completed BCG therapy without any adverse effects
|
No symptoms
|
42 (28.2%)
|
|
Completed BCG therapy with mild adverse effects
|
Mild irritative voiding symptoms, mild haematuria, fever < 38.5 °C
|
33 (22.14%)
|
|
Completed BCG therapy with dose reduction
|
Severe irritative voiding symptoms, haematuria, or symptoms lasting > 48 h
|
21 (14.1%)
|
|
Stopped BCG due to
|
|
1. Adverse effects (moderate/severe)
|
Allergic Reactions (Joint Pain, Rash)
|
23 (15.4%)
|
|
Organ Involvement (Epididymis, Liver, Lung, Kidney, Bone, Joint, Prostate)
| |
|
2. Disease progression
|
Tumour is progressing
|
10 (6.7%)
|
|
3. BCG refractory disease
|
Tumour is present at 3 months, CIS is present at both 3 and 6 months
|
7 (4.6%)
|
|
4. Recurrence during BCG
|
Tumour recurrence after initial response
|
5 (3.3%)
|
|
5. Patients’ not willing for BCG continuation
| |
8 (5.3%)
|
